Drug intelligence / Profile preview

ERC-124

Development stage: Unknown
Lead developer: Medistem
Modality: Stem Cell Therapies → Cell Therapies

Overview

**ERC-124** is a universal allogeneic stem cell therapy derived from endometrial cells, developed by Medistem Inc. (later acquired by Intrexon, now Precigen Inc.). It functions through antagonism of the interferon gamma receptor (**IFNGR**), modulating immune responses. The product was investigated for **heart failure** and other ischemic conditions, with preclinical data supporting its use in type 1 diabetes; it received FDA clearance for clinical trials but was ultimately **discontinued**.[1][6][7][10][13][18]

Targets

IFNGR1 (Interferon gamma receptor)

Beyond the preview

Go deeper on ERC-124.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ERC-124.

Explore the full profile